The plan exists. The budget does not. That, in one line, is the finding from a WHO survey of 183 countries on antimicrobial resistance — the slow, quiet process by which bacteria stop responding to the drugs designed to kill them.
Nearly every country surveyed now says it has a national action plan on AMR: 173 of 183, up from just 79 in 2017. But only 42 said their plans were financed and implemented. The rest have documents, not programmes.
From 79 to 173: The Paperwork Moved Faster Than the Money
The jump in national plans is genuinely significant. Eight years ago, most countries had no formal strategy at all. Today, political commitment is close to universal, and that is not a small achievement — it gives health ministries a framework, a set of targets and a vocabulary they can use with finance ministries.
What has not kept pace is the second half of the sentence. A plan that is neither costed nor staffed does not reduce infections. It sits in a drawer while resistance keeps spreading through hospitals, farms and communities.
Why an Unfunded Plan Is Not a Plan
Antimicrobial resistance is not solved by declarations. It is slowed by unglamorous, expensive things: laboratories that can identify which bug is which, pharmacy chains that do not sell antibiotics over the counter without a prescription, hospital infection-control teams, vaccination drives, clean water, and surveillance systems that tell a government where resistance is rising.
Each of those costs recurring money. Without it, a country can have an AMR plan and still have no ability to detect, track or contain a resistant outbreak.
The Decades of Warnings That Built This Moment
WHO has repeatedly described antimicrobial resistance as one of the top ten global public health threats. Peer-reviewed estimates have linked drug-resistant infections to more than a million deaths a year directly, with millions more associated.
The policy response followed a familiar arc. Global commitments were made, countries were asked to produce national plans, and a 2017 baseline of 79 plans became the benchmark. By this survey, that number had more than doubled. The financing questions — who pays, how much, and for how long — were left to the countries themselves.
Who Pays the Price When Resistance Wins
The consequences land disproportionately on people who cannot absorb them. A newborn with sepsis in a district hospital where the first-line antibiotic no longer works. A tuberculosis patient on a longer, harsher, costlier regimen. A farmer whose livestock die of an infection that was once treatable.
In countries where health spending is already stretched, the absence of a funded AMR plan does not mean the risk is theoretical. It means the first line of defence is often a drug that has quietly stopped working.
What WHO Is Asking Governments to Actually Fix
WHO's assessment points to the gap between adoption and execution. The organisation's message, in effect, is that the architecture is in place and the wiring is not.
The missing pieces are consistent across the 141 countries that did not report financed and implemented plans: domestic budget lines rather than donor-dependent projects, laboratory and surveillance capacity, tighter rules on antibiotic use in human and animal health, and accountability so that a plan is reviewed rather than archived.
Confirmed Facts vs What Remains Unclear
Confirmed: 173 of 183 surveyed countries report having a national action plan on AMR; 79 did in 2017. Only 42 report that their plans are financed and implemented. WHO's conclusion is that efforts have improved globally but remain off track for the 2030 goals.
Unclear: The survey captures what governments report about themselves. It does not measure whether resistance rates have actually fallen, how much money is being spent, or whether the 42 "financed and implemented" plans are delivering results. Those questions require separate data that this survey does not answer.
Where the Optimism Ends: Politics, Money and Human Behaviour
The honest reading is mixed. The rise from 79 to 173 plans shows that global health advocacy can move governments. It also shows the limits of that movement when it reaches the budget stage.
Critics of the global AMR response have long argued that plans are written to satisfy international expectations and then shelved when domestic spending is decided. Others point out that low-income countries cannot close this gap alone, and that financing pledges from wealthier nations have historically fallen short of stated needs.
There is also the behavioural problem. Antibiotics remain widely available without prescriptions in many countries, demand from patients is high, and in agriculture the drugs are used for growth promotion and disease prevention at scale.
This Is Bigger Than One Survey
AMR sits at the intersection of three trends moving in the wrong direction together: ageing populations with more chronic illness and more hospital exposure, intensifying antibiotic use in food production, and a drug pipeline that has produced few genuinely new antibiotic classes in decades.
Against that backdrop, a plan-without-funding gap is not a bureaucratic detail. It is the difference between a country that can see resistance coming and one that finds out when patients stop recovering.
What Readers, Patients and Policymakers Can Do Now
For patients: do not demand antibiotics for viral illnesses such as colds and flu, and do not stop a prescribed course early without medical advice.
For prescribers and pharmacists: the survey's logic applies at the counter — stewardship guidelines only matter if they are followed.
For policymakers: the next credible step is costing national plans and putting them into domestic health budgets, with published progress reviews, rather than reporting a plan's existence as the achievement.
For students and researchers: surveillance, diagnostics and implementation science are where the data gaps are widest, and where the 2030 goals will be won or lost.
What Happens Between Now and 2030
The arithmetic is unforgiving. If only about a quarter of surveyed countries have funded, functioning plans today, the pace of conversion would have to accelerate sharply for the 2030 targets to remain reachable.
Two paths are plausible. One is that financing follows commitment, and the plan count begins to translate into measurable reductions in resistance. The other is that the 173 figure becomes the headline achievement while the 42 remains the operational reality — and the 2030 deadline passes the way several earlier AMR milestones have.
Our Take
This is a story about the difference between signing and spending, and it is worth taking seriously precisely because the first half is a success. Getting 173 countries to agree on a shared framework for antimicrobial resistance is harder than it sounds, and it took nearly a decade.
But the survey makes the remaining problem unmissable. Antimicrobial resistance is one of the few global health threats where inaction is invisible for years and then irreversible — bacteria that develop resistance do not lose it. A country without a funded plan is not standing still; it is falling behind a moving target.
The number that matters next is not 173. It is 42 — and how quickly it grows.
Frequently Asked Questions
How many countries have a national action plan on antimicrobial resistance?
According to the WHO survey, 173 of 183 countries surveyed report having a national action plan on AMR — up from 79 countries in 2017.
How many of those plans are actually funded and implemented?
Only 42 countries said their plans were financed and implemented. That is roughly one in four of the countries surveyed, and it is the central gap WHO has flagged.
What are the 2030 goals on antimicrobial resistance?
Governments have committed to global AMR targets to be met by 2030, covering areas such as reducing resistance-related deaths and strengthening surveillance and stewardship. WHO's assessment is that current progress, while improved, is not on track to meet them.
Why does an unfunded plan matter if the country has already written it?
Because slowing resistance requires continuous spending — laboratories, surveillance, infection control, pharmacist training and restrictions on antibiotic use in farming. Without a budget, a plan cannot produce any of those, so the risk of resistant infections continues to rise even though the policy document exists.